New HHT Center of Excellence opens
Cincinnati Children’s and the University of Cincinnati Medical Center have partnered with the Cure HHT organization to open the Cincinnati Hereditary Hemorrhagic Telangiectasia (HHT) Center of Excellence. The center provides complete care for HHT patients of all ages.
“This new center is an expert clinical and research center that has true compassion for HHT patients as well as the comprehensive care necessary to treat the disease,” said Cure HHT Executive Director Marianne Clancy. “We are very excited to have them as part of our treatment network and partners in research.”
HHT, also known as Osler-Weber-Rendu Syndrome, is a genetic disease that causes malformed blood vessels, leading to sudden and extreme bleeding throughout the body. Though the disease is known for causing debilitating nosebleeds, it can also result in stroke, brain hemorrhage, heart failure and death if not treated properly. There is currently no cure for the one in 5,000 people who have it.
The Cincinnati team, led by Adrienne M. Hammill, MD, PhD, is equipped to offer all-inclusive level of care for those with HHT, from initial evaluation, diagnosis and genetic testing to the development of a treatment plan and management of that plan. The adult and pediatric interventional teams work in tandem to provide for seamless care across the lifespan, with particular expertise in treating children with brain and lung arteriovenous malformations.
Other specialties at the Cincinnati HHT Center of Excellence include cardiology, dermatology, gastroenterology, hematology, interventional radiology, otolaryngology, pulmonology, neurology and oncology.
For more information, or to make a referral, call 513-636-2084 or email hht@cchmc.org.
